IQWiG finds major benefits of Xtandi for Prostate Cancer - Astellas
According to the German Institute for Quality and Efficiency in Health Care (IQWiG), Xtandi (enzalutamide), from Astellas, shows an indication and hint of major added benefit for patients with metastatic Prostate Cancer. In November 2013, the IQWiG determined an added benefit of this drug over the appropriate comparator therapy. But based on data subsequently provided by the manufacturer in the commenting procedure, the Institute has come to a different conclusion in an addendum: there is an indication of a major added benefit in the patient group without visceral metastases.
In patients with visceral metastases, there is a hint of a major added benefit. Strong painkillers, which are often associated with severe side effects, had to be used less frequently than under BSC alone, for example.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins